van der Lely AJ - Search Results

1

The position of combined medical treatment in acromegaly.

Coopmans EC, van Meyel SWF, van der Lely AJ, Neggers SJCMM. Coopmans EC, et al. Among authors: van meyel swf, van der lely aj. Arch Endocrinol Metab. 2019 Nov-Dec;63(6):646-652. doi: 10.20945/2359-3997000000195. Arch Endocrinol Metab. 2019. PMID: 31939490 Free PMC article. Review.

2

The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.

van der Lely AJ, Harris AG, Lamberts SW. van der Lely AJ, et al. Clin Endocrinol (Oxf). 1992 Aug;37(2):181-5. doi: 10.1111/j.1365-2265.1992.tb02304.x. Clin Endocrinol (Oxf). 1992. PMID: 1395069

3

Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly.

de Herder WW, Uitterlinden P, van der Lely AJ, Hofland LJ, Lamberts SW. de Herder WW, et al. Among authors: van der lely aj. Eur J Endocrinol. 1995 Aug;133(2):195-9. doi: 10.1530/eje.0.1330195. Eur J Endocrinol. 1995. PMID: 7544670 Clinical Trial.

4

IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly.

de Herder WW, van der Lely AJ, Janssen JA, Uitterlinden P, Hofland LJ, Lamberts SW. de Herder WW, et al. Among authors: van der lely aj. Clin Endocrinol (Oxf). 1995 Oct;43(4):501-5. doi: 10.1111/j.1365-2265.1995.tb02623.x. Clin Endocrinol (Oxf). 1995. PMID: 7586626

5

Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis.

van der Lely AJ, de Herder WW, Janssen JA, Lamberts SW. van der Lely AJ, et al. J Endocrinol. 1997 Oct;155 Suppl 1:S9-13; discussion S15-6. J Endocrinol. 1997. PMID: 9389990

6

Pharmacotherapy or surgery as primary treatment for acromegaly?

Ferone D, Colao A, van der Lely AJ, Lamberts SW. Ferone D, et al. Among authors: van der lely aj. Drugs Aging. 2000 Aug;17(2):81-92. doi: 10.2165/00002512-200017020-00001. Drugs Aging. 2000. PMID: 10984197 Review.

7

New medical treatment for acromegaly.

van der Lely AJ, de Herder WW, Lamberts SW. van der Lely AJ, et al. Pituitary. 1999 Jun;2(1):89-92. doi: 10.1023/a:1009930223314. Pituitary. 1999. PMID: 11081177 Review.

8

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.

van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW. van der Lely AJ, et al. J Clin Endocrinol Metab. 2001 Feb;86(2):478-81. doi: 10.1210/jcem.86.2.7206. J Clin Endocrinol Metab. 2001. PMID: 11157994 Free article.

9

Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance.

Muller AF, Janssen JA, Hofland LJ, Lamberts SW, Bidlingmaier M, Strasburger CJ, van der Lely AJ. Muller AF, et al. Among authors: van der lely aj. J Clin Endocrinol Metab. 2001 Feb;86(2):590-3. doi: 10.1210/jcem.86.2.7173. J Clin Endocrinol Metab. 2001. PMID: 11158013 Free article.

10

Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency.

Muller AF, Leebeek FW, Janssen JA, Lamberts SW, Hofland L, van der Lely AJ. Muller AF, et al. Among authors: van der lely aj. J Clin Endocrinol Metab. 2001 Nov;86(11):5165-71. doi: 10.1210/jcem.86.11.7987. J Clin Endocrinol Metab. 2001. PMID: 11701672 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

320 results

Search Page